In a report released today, Thomas Smith from SVB Securities maintained a Hold rating on Landos Biopharma (LABP – Research Report), with a price target of $3.00. The company’s shares closed yesterday at $1.08.
According to TipRanks, Smith is an analyst with an average return of -12.2% and a 35.98% success rate. Smith covers the Healthcare sector, focusing on stocks such as Prometheus Biosciences, MannKind, and Madrigal Pharmaceuticals.
Landos Biopharma has an analyst consensus of Hold, with a price target consensus of $3.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $16.17 and a one-year low of $0.55. Currently, Landos Biopharma has an average volume of 105.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The LANCE platform identifies novel therapeutic targets based on predictions of immunometabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need.
Read More on LABP:
- Vincerx Pharma Inc (VINC) Receives a Buy from SVB Securities
- Morgan Stanley Keeps Their Buy Rating on Bioventus (BVS)
- Morgan Stanley Sticks to Their Hold Rating for Arhaus (ARHS)
- Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering
- Telsey Advisory Keeps Their Buy Rating on Holley (HLLY)
